New combo therapy aims to deepen remissions in tough leukemia
NCT ID NCT05453500
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the targeted antibody tafasitamab to a standard chemotherapy regimen (DA-EPOCH, with or without rituximab) can improve outcomes for adults newly diagnosed with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL). The study enrolls 32 adults who are not good candidates for more intensive pediatric-style treatment. The main goal is to see if more patients achieve a deep remission (negative for minimal residual disease) after one cycle of the new combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tafasitamab (a monoclonal antibody) plus chemotherapy (DA-EPOCH with or without rituximab)
- What this could lead to
- If successful, this combination could improve the chance of achieving deep remission (MRD-negative) after one cycle of treatment, potentially pointing toward a more effective first-line therapy for this type of leukemia.
- What could go wrong
- This is a small, early-phase (Phase 2) trial with only 32 participants, so results may not apply broadly. Adding tafasitamab to chemotherapy may increase side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chemo-Antibody combo beat a tough leukemia?
- New combo aims to wipe out hidden leukemia cells
- New combo therapy aims to beat leukemia without harsh chemo
- New Antibody-Drug combo aims to tackle tough leukemia
- New combo therapy aims to wipe out leukemia in adults who Can't take standard treatment
- New enzyme combo aims to boost leukemia treatment in High-Risk adults